Extrapulmonary small cell carcinoma in breast and prostate

Rivero, J. Quirós; García, Julia Luisa Muñoz; Rodriguez, J.J. Cabrera; Ferreira, José Antonio González; Ots, P. Samper; Kavadoy, Y. Ríos

doi:10.1007/s12094-009-0427-6

Cited by 6 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the cases described in the literature report a high Ki-67 of >20%. [1,12,[14][15][16]31,33,42,46,48,49,68,69] TTF-1 was negative in our case, supporting the diagnosis of a non-pulmonary SCC, as 90% of pulmonary SCC express this marker. [71] Interestingly however, TTF-1 has been reported positive in a few cases of breast SCC, so this again cannot be used as a reliable indicator to determine origin.…”

Section: Pathologic Featuressupporting

confidence: 70%

“…Our literature search revealed 66 English language case reports, [1–8,11–69] describing the clinical course of 91 patients with poorly differentiated neuroendocrine breast cancer (Supplemental Digital Content Table S1, http://links.lww.com/MD/G590). The first case was reported by Wade et al .…”

Section: Discussion and Literature Reviewmentioning

confidence: 99%

“…Most of the cases described in the literature report a high Ki-67 of >20%. [ 1 , 12 , 14 – 16 , 31 , 33 , 42 , 46 , 48 , 49 , 68 , 69 ]…”

Section: Pathologic Featuresmentioning

confidence: 99%

“…[ 23 ] For early stage or locally advanced breast SCC, numerous systemic therapy regimens have been utilized. These include 5-fluorouracil, doxorubicin, and cyclophosphamide followed by paclitaxel and etoposide (with a partial response, [ 31 ] irinotecan and carboplatin followed by radiotherapy (with a complete response), [ 32 ] docetaxel and cyclophosphamide (with a partial pathologic response), [ 15 ] and 5-fluorouracil, epirubicin and cyclophosphamide (with no pathologic response). [ 26 ] Some cases were treated with up-front mastectomy and axillary lymph node dissection, with or without adjuvant treatment.…”

Section: Management and Prognosismentioning

confidence: 99%

“…However, after treatment the subsequent biopsies from the axilla and from the paratracheal lymphadenopathy showed trends towards positivity for neuroendocrine markers, negativity for breast markers and higher Ki-67. Most of the cases described in the literature report a high Ki-67 of >20% [1,12,14–16,31,33,42,46,48,49,68,69] …”

Section: Pathologic Featuresmentioning

confidence: 99%

See 4 more Smart Citations

Evolution of an invasive ductal carcinoma to a small cell carcinoma of the breast

et al. 2022

View full text Add to dashboard Cite

Rationale: Small cell carcinoma (SCC) is a rare subtype of breast cancer and presents a complex diagnostic and treatment challenge, due to paucity of data. To the best of our knowledge, most cases of breast SCC reported in the literature describe a de novo breast primary. Our case is unique as it describes the evolution of an invasive ductal carcinoma after treatment into a SCC of the breast. Patient concerns and diagnosis: We report a case of a 53-year-old female, lifelong non-smoker, who initially presented with breast mass noted on self examination. Breast and axillary lymph node biopsy demonstrated a hormone receptor positive invasive ductal carcinoma with a metastatic T3 lesion. Intervention: She was treated with first-line palbociclib/letrozole with initial clinical response, and at progression was switched to capecitabine with no response. Repeat biopsy of the axillary lesion showed evolution of the tumor into a triple negative breast cancer. She was then treated with third-line paclitaxel and radiation therapy with good initial response. She eventually had further disease progression and presented with a new mediastinal lymphadenopathy causing SVC syndrome. Biopsy of this showed a small cell variant of breast neuroendocrine carcinoma. Due to the evolution of histology in this case, a retrospective review of her initial breast specimen as well as the second biopsy from the axilla was conducted which confirmed that the mediastinal lymphadenopathy was metastatic from the original breast tumor. Outcomes and lessons: We speculate that the initial treatment allowed a minority of treatment-resistant neuroendocrine cells to grow and become the dominant face of the tumor. Our patient had an excellent response to carboplatin/etoposide and consolidative locoregional radiotherapy but presented with an early intracranial recurrence. This is a similar pattern of metastases as seen in lung SCC and highlights a potential role for prophylactic cranial irradiation in breast SCC. Further studies are needed to better understand the biology and treatment of breast SCC which continues to present a challenge for clinicians.

show abstract